Connor, Clark & Lunn Investment Management (CC&L)
KLRS

Connor, Clark & Lunn Investment Management (CC&L)’s Kalaris Therapeutics KLRS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.8K Buy
13,655
+3,496
+34% +$31K ﹤0.01% 1506
2025
Q4 		$85.7K Buy
+10,159
New +$65K ﹤0.01% 1487

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KLRS Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Kalaris Therapeutics (KLRS) stake by 34% in Q1 2026, buying an estimated $31K and bringing the position to 13,655 shares worth $78.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KLRS in Q4 2025 and has held it in 2 quarters since. The position peaked at $85.7K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 13,655 shares of Kalaris Therapeutics worth $78.8K as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 3,496 Kalaris Therapeutics shares in Q1 2026, an estimated $31K.
  • Kalaris Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1506 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Kalaris Therapeutics position peaked at $85.7K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.